Question 1

What is RUXOLITINIB used for?

Accepted Answer

RUXOLITINIB (brand name OPZELURA) is a JAK Inhibitor indicated for other Janus kinase (JAK) inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended..

Question 2

How does RUXOLITINIB work?

Accepted Answer

RUXOLITINIB works through the following mechanism: 12.1 Mechanism of Action Ruxolitinib, a Janus kinase (JAK) inhibitor, inhibits JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation and subsequent localization of STATs to the nucleus leading to modulation of gene expression. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known..

Question 3

What are the most common side effects of RUXOLITINIB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for RUXOLITINIB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is RUXOLITINIB the same as OPZELURA?

Accepted Answer

OPZELURA is a brand name for RUXOLITINIB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

RUXOLITINIB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations